| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
103.36(B) |
| Last
Volume: |
682,467 |
Avg
Vol: |
1,619,368 |
| 52
Week Range: |
$323.57 - $446.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
67,740 |
152,280 |
258,193 |
599,211 |
| Total Sell Value |
$28,555,052 |
$61,805,647 |
$99,413,137 |
$200,212,570 |
| Total People Sold |
8 |
12 |
15 |
18 |
| Total Sell Transactions |
28 |
41 |
68 |
132 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2023-03-24 |
4 |
AS |
$305.38 |
$539,912 |
D/D |
(1,768) |
49,611 |
|
11% |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2023-03-17 |
4 |
AS |
$294.52 |
$592,786 |
D/D |
(2,000) |
51,379 |
|
18% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-03-16 |
4 |
AS |
$300.54 |
$825,423 |
D/D |
(2,746) |
49,268 |
|
17% |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2023-03-13 |
4 |
AS |
$288.31 |
$783,346 |
D/D |
(2,666) |
53,379 |
|
24% |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2023-03-10 |
4 |
AS |
$286.64 |
$604,709 |
D/D |
(2,088) |
56,045 |
|
26% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2023-02-27 |
4 |
AS |
$287.23 |
$1,218,449 |
D/D |
(4,238) |
32,038 |
|
18% |
|
| Ambrose Kristen |
SVP & Chief Accounting Officer |
• – – |
2023-02-27 |
4 |
AS |
$287.25 |
$347,072 |
D/D |
(1,207) |
7,303 |
|
18% |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2023-02-27 |
4 |
AS |
$287.20 |
$101,768 |
D/D |
(354) |
56,805 |
|
18% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2023-02-27 |
4 |
AS |
$287.16 |
$1,447,143 |
D/D |
(5,034) |
56,556 |
|
18% |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2023-02-24 |
4 |
D |
$289.12 |
$2,713,680 |
D/D |
(9,386) |
129,969 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$1,147,806 |
D/D |
(3,970) |
36,276 |
|
- |
|
| Ambrose Kristen |
SVP & Chief Accounting Officer |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$145,138 |
D/D |
(502) |
8,510 |
|
- |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$956,409 |
D/D |
(3,308) |
57,159 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$1,147,806 |
D/D |
(3,970) |
52,014 |
|
- |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$1,362,912 |
D/D |
(4,714) |
61,590 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$713,548 |
D/D |
(2,468) |
66,518 |
|
- |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$956,409 |
D/D |
(3,308) |
58,133 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$956,409 |
D/D |
(3,308) |
63,207 |
|
- |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2023-02-24 |
4 |
D |
$289.12 |
$3,969,618 |
D/D |
(13,730) |
48,349 |
|
- |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2023-02-22 |
4 |
AS |
$291.84 |
$706,679 |
D/D |
(2,401) |
66,304 |
|
18% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2023-02-21 |
4 |
AS |
$291.01 |
$705,596 |
D/D |
(2,402) |
68,705 |
|
20% |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2023-02-21 |
4 |
AS |
$291.01 |
$141,002 |
D/D |
(480) |
60,467 |
|
20% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2023-02-21 |
4 |
AS |
$291.01 |
$1,175,676 |
D/D |
(4,002) |
40,246 |
|
20% |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2023-02-17 |
4 |
D |
$292.85 |
$2,740,783 |
D/D |
(9,359) |
139,355 |
|
- |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2023-02-17 |
4 |
D |
$292.85 |
$1,317,239 |
D/D |
(4,498) |
71,107 |
|
- |
|
3258 Records found
|
|
Page 7 of 131 |
|
|
0.22 (0.06%) 
